Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Brandon Faulkner

Nurse Practitioner, Acute Care Fort Smith, AR Nurse Practitioner

NPI 1710381082 CMS profile 10947583

302 N Greenwood Ave, Fort Smith, AR 72901

Open in the dashboard

General payments

$5,087

134 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Brandon Faulkner of Fort Smith, AR is reported in the CMS Open Payments database as having received $5,087 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $26 1
2023 General $1,318 48
2022 General $1,140 43
2021 General $2,604 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandon Faulkner
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Brandon Faulkner were reported at $0. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Brandon Faulkner Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,604 $123 $38–$327 $132
2022 $1,140 $130 $44–$369 $149
2023 $1,318 $144 $49–$410 $160
2024 $26 $146 $48–$433 $164
2025 $0 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Medtronic, Inc. $2,569 40 payments
  2. Abbott Laboratories $894 14 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $387 25 payments
  4. Eisai Inc. $355 16 payments
  5. TerSera Therapeutics LLC $331 9 payments
  6. Collegium Pharmaceutical, Inc. $205 11 payments
  7. GRT US Holding, Inc. $118 8 payments
  8. Horizon Therapeutics plc $54 3 payments
  9. Boston Scientific Corporation $53 1 payment
  10. Alnylam Pharmaceuticals Inc. $50 2 payments
  11. Other $72 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $3,332 119 payments
  2. Travel and Lodging $1,525 11 payments
  3. Education $231 4 payments
Products named General payments · program years 2021–2024
  1. INTELLIS $1,748 14 payments
  2. RELISTOR $387 25 payments
  3. PROCLAIM Neuromodulation $362 7 payments
  4. Dayvigo $355 16 payments
  5. Prialt $331 9 payments
  6. PROCLAIM Neuromodulation $307 3 payments
  7. SYNCHROMED $202 5 payments
  8. VANTA ADAPTIVESTIM $176 8 payments
  9. PROCLAIM Neuromodulation $144 3 payments
  10. INTELLIS ADAPTIVESTIM $134 7 payments
  11. Other $722 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$8,475

Medicare's payments for the services billed

Medicare patients

37

Average age 75

Services billed

129

18 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 70%
Heart failure 68%
Diabetes 59%
Chronic kidney disease 57%
Arthritis 51%
Atrial fibrillation 49%
COPD 49%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record